Carcinoma, Non-Small-Cell Lung
Conditions
Keywords
Lung cancer, DRibble Vaccine, Imiquimod, GM-CSF, HPV vaccine (Ceravix), Cyclophosphamide
Brief summary
This study will test an investigational vaccine, called DRibbles, for the treatment of non-small cell lung cancer (NSCLC). We hypothesize that vaccination with the DRibble vaccine will cause an immune responses against proteins contained in the DRibble vaccine and the protein antigens targeted by this strong immune response will include common antigens shared by both the vaccine and the patient's tumor.
Detailed description
This is an open-label, randomized study in which the first 33 patients will be assigned to receive the either: * DRibbles vaccine and HPV vaccine * DRibbles vaccine, HPV vaccine, and imiquimod * DRibbles vaccine, HPV vaccine, and GM-CSF After 11 patients have been assigned to each group, the study arm with the greatest number of vaccine-induced strong antibody responses will then continue with enrollment of 15 further patients. The primary objective is to determine the best strategy to induce strong (\>15 fold) tumor-specific or tumor-associated antibody responses in patients with stage III A and B NSCLC. The goal is to select one regimen to advance to additional clinical trials.
Interventions
DRUGCyclophosphamide
Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy.
BIOLOGICALDRibble vaccine
DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43.
DRUGImiquimod
Imiquimod cream (5%, 250 mg containing 12.5 mg imiquimod - one packet/day) will be self applied once per day starting with the second vaccine (week 4). Immediately following vaccination and for four days following each vaccine cycle (total 5 days) imiquimod will be applied to a 4 x 5-cm outlined area of healthy extremity skin that includes the vaccine site.
DRUGGM-CSF
GM-CSF will be administered at 50 mcg/day starting with the second vaccine (week 4) and continuing with each subsequent vaccine. A volume of 0.2 cc will be delivered by the CADD-MSTM 3 Ambulatory infusion pump at a rate of 0.008 cc/hr. The pump will be refilled after three days for a total of six days of infusion.
BIOLOGICALHPV vaccine
Immunization with HPV vaccine will consist of two 0.5-mL intramuscular injection at the time of the first and third vaccinations. The preferred site of administration is the deltoid region of the upper arm.
Sponsors
National Cancer Institute (NCI)
Providence Cancer Center, Earle A. Chiles Research Institute
Providence Health & Services
Mayo Clinic
Louisiana State University Health Sciences Center in New Orleans
UbiVac
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Stage IIIA or IIIB histologically proven non-small cell lung cancer * Completion of definitive therapy * Enrollment from 28 days to 12 weeks from completion of definitive therapy * Toxicities from definitive therapy resolved to less than grade 1 * ECOG performance status 0-1 * Negative pregnancy test in women of childbearing potential * Agree to avoid pregnancy or fathering a child while on study treatment * Ability to give informed consent and comply with protocol * Anticipated survival minimum of 6 months * Prior therapy with investigational agents must be completed at least 3 weeks prior to study enrollment * Normal organ and marrow function as defined by specific lab tests * Archived tumor tissue available
Exclusion criteria
* Active autoimmune disease except for vitilogo or hypothyroidism * Active other malignancy * Known HIV+ and/or Hepatitis B or C positive * Medical or psychiatric conditions that would preclude safe participation * Ongoing chemotherapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Identify the regimen that produces the strongest antibody response | 95 days | The best regimen will be defined as the one that generates the greatest increase in the number of strong antibody responses as defined by a greater than 15-fold increase in antibody, as measured using the Immune Response Biomarker Profiling Array (Invitrogen) on the day 95 serum sample. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety | 43 weeks | To evaluate the overall safety of allogeneic NSCLC DRibble vaccine alone or in combination with either imiquimod or GM-CSF, as adjuvant treatment for definitively-treated patients with Stage IIIA or B NSCLC. During the treatment period, patients will be seen in clinic 13 times over a 22-week period; performance status and side-effects will be evaluated at each visit. |
| Progression free survival | 2 years | Evaluate progression-free survival. Tumor measurements by CT scan will be obtained at week 16 and subsequently at the discretion of the treating investigator. After the treatment period, patients will be seen every 3 months for 2 years, or until progressive disease. |
| Immune response and progression-free survival correlation. | 2 years | Evaluate whether any immune response data correlate with progression-free survival. Immune response data will be collected 12 times over the first 43 weeks and then every 3 months until two years or progressive disease. This data will be correlated with progression-free survival. |
Countries
United States
Outcome results
None listed